Gastrointestinal Stromal Tumors Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1064784
  • May 2021
  • Pharmaceuticals
  • 146 Pages
The Gastrointestinal Stromal Tumors Therapeutics Market research report comprises of an overall in depth-analysis such as market drivers, opportunities, restraints, latest developments and trends, segmentation of the market, competitive analysis, global as well as regional analysis by showcasing how each of these factors can improve the further growth of the market on an overall perspective. The report also showcases the overall market value which includes the historic data (2018-2019) and forecast data (2020-2028) generated through the revenue (USD Mn)
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2020
Forecast Period Covered 2020 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Companies Covered AROG Pharmaceuticals, INC., Bayer AG, Boston Biomedical, Celldex Therapeutics, F. Hoffmann-La Roche Ltd, Immunicum AB., NATCO Pharma Limited, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd.
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

COVID-19 Coverage
With the beginning of the COVID-19 pandemic in early 2020, all major economies around the world enforced severe lockdown restrictions to curb the spread of the virus. Apart from a few sectors such as healthcare and related essential services, most of the industries suffered tremendously due to inability to function in a normal fashion. Moreover, even some of the essential sectors suffered due to delays caused by supply chain disruptions and other travel complexities. However, with massive vaccination drives in most of the developed economies, some of the economies across the world experienced economic recovery from 2021. The Gastrointestinal Stromal Tumors Therapeutics market is expected to gain momentum in such economies and probably recover some of the losses inflicted in the year 2020. With continued efforts towards curbing the virus in the developing economies, the Gastrointestinal Stromal Tumors Therapeutics market is expected to attain Pre COVID-19 levels by mid-2022.

Gastrointestinal Stromal Tumors Therapeutics Report’s Assessment
The research report is formulated such that it offers a deep understating on the market drivers that are assimilating the growth of the market, the market opportunities that are going to provide future growth factors for the market and the market restraints which showcase the reasons as to why the market can get hampered and dissimilated. All these factors are considered keeping in view the historic and forecast analysis which can enlighten the above mentioned factors.

Thereby at a glance a reader can understand all the factors and prospects of the Gastrointestinal Stromal Tumors Therapeutics market and how it can assimilate and dissimilate based on each of the factors and figures mentioned in the report

Gastrointestinal Stromal Tumors Therapeutics Market Competitive and Premeditated Analysis
In the Gastrointestinal Stromal Tumors Therapeutics report major factors such latest tactical developments, competitors, research and development, participation of each region in the market and the competition among them, the latest news regarding company acquisitions and product launch, revenue of the competitors as well as the key offerings they provide all these factors are mentioned in the report with reasons to justify and understand them in depth.

The readers and purchaser of the Gastrointestinal Stromal Tumors Therapeutics research report can gain a comprehensive understanding of the market competition, the revenue of each major players and their contribution towards the market, attractive proposition analysis is provided in the report which sub divides the segments with respect to the largest segment that has contributed to the market growth and the fastest growing segment based on the size of the market as well as its overall appeal.
 
Major Key Players for Global Gastrointestinal Stromal Tumors Therapeutics Market:
The Gastrointestinal Stromal Tumors Therapeutics market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. AROG Pharmaceuticals, INC., Bayer AG, Boston Biomedical, Celldex Therapeutics, F. Hoffmann-La Roche Ltd, Immunicum AB., NATCO Pharma Limited, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd.

The Gastrointestinal Stromal Tumors Therapeutics market report showcases vast potentials of growth and assimilation which is going to provide the industry numerous opportunities to grow and generate revenue by understanding the segments and which segment is a potential part to increase the disposable income in the present and upcoming years.

Gastrointestinal Stromal Tumors Therapeutics Market Segmentation Analysis:
Each of the segment is explained in brief along with the revenue it generates for the market based on the historic and forecast data by highlighting the largest segment and the fastest growing segment with reasons to justify it.

The Global segmentation of the Gastrointestinal Stromal Tumors Therapeutics market:
by Route Of Administration
Oral
Parenteral
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Regional Analysis of the Gastrointestinal Stromal Tumors Therapeutics market:
The Gastrointestinal Stromal Tumors Therapeutics market is dived based on different regions such as North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. And the analysis of each region is provided by highlighting the largest contribution region, the fastest growing region and the factors that is keeping the market active in the other regions is also mentioned in depth. Each regional segment also comprises of the revenue each segment holds in a specific region with reasons to justify the values.

By Regions:
  • North America (U.S and Canada)
  • Europe (U.K., Germany and France)
  • Asia Pacific (China, India and Japan)
  • Latin America (Mexico and Brazil)
  • Middle East and Africa (GCC Countries and South Africa)
 


Major Factors Included and highlighted in the Gastrointestinal Stromal Tumors Therapeutics report are as follows:
  • The overall market value along with historic and future data analysis.
  • The Growth drivers, opportunities and restraints are mention in detail.
  • The size of the entire Gastrointestinal Stromal Tumors Therapeutics market on a global perspective.
  • The CAGR value of the overall market from 2020 to 2028.
  • COVID-19 impact on the Gastrointestinal Stromal Tumors Therapeutics market and how it is coping up with the situation.
  • Major competitors and their contribution towards the market.
  • The segmentation analysis is included which provides a clear picture of the market bifurcation.
  • Tables and graphs that can easily been understood at a glance
  • Latest trends and news related to the Gastrointestinal Stromal Tumors Therapeutics market is included in the report.
Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Gastrointestinal Stromal Tumors Therapeutics market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Gastrointestinal Stromal Tumors Therapeutics market for numerous purposes such as:

     1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

     2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Gastrointestinal Stromal Tumors Therapeutics market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Gastrointestinal Stromal Tumors Therapeutics market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

     3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Gastrointestinal Stromal Tumors Therapeutics market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Manufacturers and Segments

  • AROG Pharmaceuticals, INC.
  • Bayer AG
  • Boston Biomedical
  • Celldex Therapeutics
  • F. Hoffmann-La Roche Ltd
  • Immunicum AB.
  • NATCO Pharma Limited
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Oral
  • Parenteral
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Gastrointestinal Stromal Tumors Therapeutics Market Snapshot
          2.1.1. Global Gastrointestinal Stromal Tumors Therapeutics Market By Route Of Administration,2019
               2.1.1.1.Oral
               2.1.1.2.Parenteral
          2.1.2. Global Gastrointestinal Stromal Tumors Therapeutics Market By Distribution Channel,2019
               2.1.2.1.Hospital Pharmacies
               2.1.2.2.Retail Pharmacies
               2.1.2.3.Online Pharmacies
          2.1.3. Global Gastrointestinal Stromal Tumors Therapeutics Market By End-use,2019
          2.1.4. Global Gastrointestinal Stromal Tumors Therapeutics Market By Geography,2019

3. Global Gastrointestinal Stromal Tumors Therapeutics Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By Route Of Administration, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Route Of Administration, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Route Of Administration, 2020
     4.2. Global Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By Route Of Administration, 2018 – 2028

5. Global Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By Distribution Channel, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Distribution Channel, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Distribution Channel, 2020
     5.2. Global Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By Distribution Channel, 2018 – 2028

6. Global Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By End-use, 2018 – 2028

7. Global Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Gastrointestinal Stromal Tumors Therapeutics Market Analysis, 2018 – 2028 
          7.2.1. North America Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By Route Of Administration, 2018 – 2028
          7.2.3. North America Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By Distribution Channel, 2018 – 2028
          7.2.4. North America Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Gastrointestinal Stromal Tumors Therapeutics Market Analysis, 2018 – 2028 
          7.3.1.  Europe Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By Route Of Administration, 2018 – 2028
          7.3.3. Europe Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By Distribution Channel, 2018 – 2028
          7.3.4. Europe Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Gastrointestinal Stromal Tumors Therapeutics Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By Route Of Administration, 2018 – 2028
          7.4.3. Asia Pacific Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By Distribution Channel, 2018 – 2028
          7.4.4. Asia Pacific Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Gastrointestinal Stromal Tumors Therapeutics Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By Route Of Administration, 2018 – 2028
          7.5.3. Latin America Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By Distribution Channel, 2018 – 2028
          7.5.4. Latin America Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Gastrointestinal Stromal Tumors Therapeutics Market Analysis, 2018 – 2028 
          7.6.1.  MEA Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By Route Of Administration, 2018 – 2028
          7.6.3. MEA Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By Distribution Channel, 2018 – 2028
          7.6.4. MEA Gastrointestinal Stromal Tumors Therapeutics Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Gastrointestinal Stromal Tumors Therapeutics Providers
        8.4.1 AROG Pharmaceuticals, INC.
                8.4.1.1 Business Description
                8.4.1.2 AROG Pharmaceuticals, INC. Geographic Operations
                8.4.1.3 AROG Pharmaceuticals, INC. Financial Information
                8.4.1.4 AROG Pharmaceuticals, INC. Product Positions/Portfolio
                8.4.1.5 AROG Pharmaceuticals, INC. Key Developments
        8.4.2 Bayer AG
                8.4.2.1 Business Description
                8.4.2.2 Bayer AG Geographic Operations
                8.4.2.3 Bayer AG Financial Information
                8.4.2.4 Bayer AG Product Positions/Portfolio
                8.4.2.5 Bayer AG Key Developments
        8.4.3 Boston Biomedical
                8.4.3.1 Business Description
                8.4.3.2 Boston Biomedical Geographic Operations
                8.4.3.3 Boston Biomedical Financial Information
                8.4.3.4 Boston Biomedical Product Positions/Portfolio
                8.4.3.5 Boston Biomedical Key Developments
        8.4.4 Celldex Therapeutics
                8.4.4.1 Business Description
                8.4.4.2 Celldex Therapeutics Geographic Operations
                8.4.4.3 Celldex Therapeutics Financial Information
                8.4.4.4 Celldex Therapeutics Product Positions/Portfolio
                8.4.4.5 Celldex Therapeutics Key Developments
        8.4.5 F. Hoffmann-La Roche Ltd
                8.4.5.1 Business Description
                8.4.5.2 F. Hoffmann-La Roche Ltd Geographic Operations
                8.4.5.3 F. Hoffmann-La Roche Ltd Financial Information
                8.4.5.4 F. Hoffmann-La Roche Ltd Product Positions/Portfolio
                8.4.5.5 F. Hoffmann-La Roche Ltd Key Developments
        8.4.6 Immunicum AB.
                8.4.6.1 Business Description
                8.4.6.2 Immunicum AB. Geographic Operations
                8.4.6.3 Immunicum AB. Financial Information
                8.4.6.4 Immunicum AB. Product Positions/Portfolio
                8.4.6.5 Immunicum AB. Key Developments
        8.4.7 NATCO Pharma Limited
                8.4.7.1 Business Description
                8.4.7.2 NATCO Pharma Limited Geographic Operations
                8.4.7.3 NATCO Pharma Limited Financial Information
                8.4.7.4 NATCO Pharma Limited Product Positions/Portfolio
                8.4.7.5 NATCO Pharma Limited Key Developments
        8.4.8 Novartis AG
                8.4.8.1 Business Description
                8.4.8.2 Novartis AG Geographic Operations
                8.4.8.3 Novartis AG Financial Information
                8.4.8.4 Novartis AG Product Positions/Portfolio
                8.4.8.5 Novartis AG Key Developments
        8.4.9 Pfizer Inc.
                8.4.9.1 Business Description
                8.4.9.2 Pfizer Inc. Geographic Operations
                8.4.9.3 Pfizer Inc. Financial Information
                8.4.9.4 Pfizer Inc. Product Positions/Portfolio
                8.4.9.5 Pfizer Inc. Key Developments
        8.4.10 Sun Pharmaceutical Industries Ltd.
                8.4.10.1 Business Description
                8.4.10.2 Sun Pharmaceutical Industries Ltd. Geographic Operations
                8.4.10.3 Sun Pharmaceutical Industries Ltd. Financial Information
                8.4.10.4 Sun Pharmaceutical Industries Ltd. Product Positions/Portfolio
                8.4.10.5 Sun Pharmaceutical Industries Ltd. Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Gastrointestinal Stromal Tumors Therapeutics Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Gastrointestinal Stromal Tumors Therapeutics Market Revenue, By Route Of Administration, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Gastrointestinal Stromal Tumors Therapeutics Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Gastrointestinal Stromal Tumors Therapeutics Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Gastrointestinal Stromal Tumors Therapeutics Market Revenue, By Route Of Administration, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Gastrointestinal Stromal Tumors Therapeutics Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Gastrointestinal Stromal Tumors Therapeutics Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Gastrointestinal Stromal Tumors Therapeutics Market Revenue, By Route Of Administration, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Gastrointestinal Stromal Tumors Therapeutics Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Gastrointestinal Stromal Tumors Therapeutics Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Gastrointestinal Stromal Tumors Therapeutics Market Revenue, By Route Of Administration, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Gastrointestinal Stromal Tumors Therapeutics Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Gastrointestinal Stromal Tumors Therapeutics Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Gastrointestinal Stromal Tumors Therapeutics Market Revenue, By Route Of Administration, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Gastrointestinal Stromal Tumors Therapeutics Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Gastrointestinal Stromal Tumors Therapeutics Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Gastrointestinal Stromal Tumors Therapeutics: Market Segmentation 
FIG. 2 Global Gastrointestinal Stromal Tumors Therapeutics Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Gastrointestinal Stromal Tumors Therapeutics Market, By Route Of Administration, 2019 (US$ Mn) 
FIG. 5 Global Gastrointestinal Stromal Tumors Therapeutics Market, By Distribution Channel, 2019 (US$ Mn) 
FIG. 6 Global Gastrointestinal Stromal Tumors Therapeutics Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Gastrointestinal Stromal Tumors Therapeutics Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Gastrointestinal Stromal Tumors Therapeutics Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Gastrointestinal Stromal Tumors Therapeutics Providers, 2019
FIG. 11 Global Gastrointestinal Stromal Tumors Therapeutics Market Revenue Contribution, By Route Of Administration, 2019 & 2028 (Value %) 
FIG. 12 Global Gastrointestinal Stromal Tumors Therapeutics Market Revenue Contribution, By Distribution Channel, 2019 & 2028 (Value %) 
FIG. 13 Global Gastrointestinal Stromal Tumors Therapeutics Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Gastrointestinal Stromal Tumors Therapeutics Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Gastrointestinal Stromal Tumors Therapeutics Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Gastrointestinal Stromal Tumors Therapeutics Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Gastrointestinal Stromal Tumors Therapeutics Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Gastrointestinal Stromal Tumors Therapeutics Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Gastrointestinal Stromal Tumors Therapeutics market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Gastrointestinal Stromal Tumors Therapeutics Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Gastrointestinal Stromal Tumors Therapeutics Market Value, By Segment1, 2018 – 2028
TABLE  North America Gastrointestinal Stromal Tumors Therapeutics Market Value, By Segment2, 2018 – 2028
TABLE  North America Gastrointestinal Stromal Tumors Therapeutics Market Value, By Country, 2018 – 2028
TABLE  Europe Gastrointestinal Stromal Tumors Therapeutics Market Value, By Segment1, 2018 – 2028
TABLE  Europe Gastrointestinal Stromal Tumors Therapeutics Market Value, By Segment2, 2018 – 2028
TABLE  Europe Gastrointestinal Stromal Tumors Therapeutics Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Gastrointestinal Stromal Tumors Therapeutics Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Gastrointestinal Stromal Tumors Therapeutics Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Gastrointestinal Stromal Tumors Therapeutics Market Value, By Country, 2018 – 2028
TABLE  Latin America Gastrointestinal Stromal Tumors Therapeutics Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Gastrointestinal Stromal Tumors Therapeutics Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Gastrointestinal Stromal Tumors Therapeutics Market Value, By Country, 2018 – 2028
TABLE  MEA Gastrointestinal Stromal Tumors Therapeutics Market Value, By Segment1, 2018 – 2028
TABLE  MEA Gastrointestinal Stromal Tumors Therapeutics Market Value, By Segment2, 2018 – 2028
TABLE  MEA Gastrointestinal Stromal Tumors Therapeutics Market Value, By Country, 2018 – 2028
TABLE  AROG Pharmaceuticals, INC.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Bayer AG: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Boston Biomedical: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Celldex Therapeutics: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  F. Hoffmann-La Roche Ltd: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Immunicum AB.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  NATCO Pharma Limited: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Novartis AG: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Pfizer Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Sun Pharmaceutical Industries Ltd.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Gastrointestinal Stromal Tumors Therapeutics Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Gastrointestinal Stromal Tumors Therapeutics Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Gastrointestinal Stromal Tumors Therapeutics Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Gastrointestinal Stromal Tumors Therapeutics Market, By Geography, 2019 (US$ Mn)
FIG.  Global Gastrointestinal Stromal Tumors Therapeutics Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Gastrointestinal Stromal Tumors Therapeutics Providers, 2016
FIG.  Global Gastrointestinal Stromal Tumors Therapeutics Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Parenteral Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Gastrointestinal Stromal Tumors Therapeutics Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Retail Pharmacies Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Online Pharmacies Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Gastrointestinal Stromal Tumors Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Gastrointestinal Stromal Tumors Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Gastrointestinal Stromal Tumors Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Gastrointestinal Stromal Tumors Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Gastrointestinal Stromal Tumors Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Gastrointestinal Stromal Tumors Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Gastrointestinal Stromal Tumors Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Gastrointestinal Stromal Tumors Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Gastrointestinal Stromal Tumors Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Gastrointestinal Stromal Tumors Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Gastrointestinal Stromal Tumors Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Gastrointestinal Stromal Tumors Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Gastrointestinal Stromal Tumors Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Gastrointestinal Stromal Tumors Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Gastrointestinal Stromal Tumors Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Gastrointestinal Stromal Tumors Therapeutics Market Value, 2018 – 2028, (US$ Mn)